Where Discovery Leads: CAR-T with Sarah K. Tasian, MD

In modern times we do a very good job at curing many children with acute myeloid leukemia (AML).

However, for those children who relapse, resistance to chemotherapy remains a major problem.

And during the past decade we have worked very hard in our research laboratories to

identify new immunotherapies for pediatric AML that we hope aim to overcome this chemotherapy resistance.

I'm excited that we've been able to translate some of the most promising results from our labs to early phase clinical trials.

And we're now studying several antibody or CAR-T cell immunotherapies in children with relapse AML, trying to learn the safety and the potential efficacy of these new treatments.

However, a lot of work still needs to be done in the labs with respect to new target identification as well as new cell therapy modalities and we hope that these new data will lead to our next generation of clinical trails for children in the near future.

AML remains a clinical challenge for us in pediatric oncology, but we are very excited about the recent and ongoing progress, especially in the field of immunotherapy.